Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam, Tekmira Form New RNAi Drug-Delivery Collaboration

Premium

Alnylam Pharmaceuticals and Tekmira Pharmaceuticals this week announced that they have begun a new research collaboration focused on discovering novel cationic lipids and lipid nanoparticles for systemic delivery of RNAi drugs.

Under the terms of the two-year deal, Alnylam will have the exclusive rights to all new inventions resulting from the alliance, as well as the rights to sublicense any related intellectual property. Tekmira will have the right to use new inventions with its own RNAi therapeutics.

Alnylam will fund the collaboration, which will include research conducted at the University of British Columbia and a new company called AlCana Technologies. Additional terms of the arrangement were not disclosed.

The Scan

Close Panel Vote on Califf Nomination

The New York Times reports there was a close committee vote to advance the nomination of Robert Califf to lead the US Food and Drug Administration to the full Senate.

Task Force Reports on Scientific Integrity

Nature News writes that that a new task force report recommends that the US establish a cross-agency scientific integrity council.

Across the Hall

Genetic testing, closed-circuit cameras, and more show how a traveler, without any contact, infected others at a New Zealand quarantine facility, CNN reports.

Science Paper Examines Influence of Chromatin Modifications on Obsessive-Compulsive Disorder

In Science this week: genes regulating chromatin modification may contribute to OCD risk.